cytarabine has been researched along with transforming growth factor beta in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lotem, J; Sachs, L | 1 |
| Coffey, RJ; Pierce, DF | 1 |
| Bloch, A | 1 |
| de Vries, P; Singer, JW | 1 |
| Audet, JN; Gowing, G; Julien, JP; Paradis, R; Soucy, G | 1 |
| Andreeff, M; Hatanaka, Y; Hsu, FJ; Jin, L; Konopleva, M; Miida, T; Shi, YX; Shikami, M; Tabe, Y; Zeng, Z | 1 |
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
7 other study(ies) available for cytarabine and transforming growth factor beta
| Article | Year |
|---|---|
Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azides; Cell Survival; Cycloheximide; Cytarabine; Cytokines; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Interferon Type I; Interleukin-1; Interleukin-3; Interleukin-6; Leukemia, Experimental; Leukemia, Myeloid; Mice; Recombinant Proteins; Sodium Azide; Stem Cell Factor; Transforming Growth Factor beta; Tumor Cells, Cultured; Vincristine | 1992 |
Therapeutic manipulation of cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine.
Topics: Animals; Cytarabine; Digestive System; Drug Administration Schedule; Erythrocyte Count; Hematopoietic Stem Cells; Leukocyte Count; Leukopenia; Male; Mice; Mice, Inbred A; Mice, Inbred DBA; Mice, Inbred Strains; Neutropenia; Platelet Count; S Phase; Stem Cells; Survival Rate; Transforming Growth Factor beta | 1994 |
Dynamics of interaction between DNA-specific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Differentiation; Cytarabine; Cytokines; Dactinomycin; Daunorubicin; DNA, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Monocytes; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1993 |
Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Chemokine CCL4; Cisplatin; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Etoposide; Female; Growth Inhibitors; Hematopoietic Stem Cells; Macrophage Inflammatory Proteins; Melphalan; Mice; Mice, Inbred BALB C; Pentoxifylline; Spleen; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2000 |
Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Proliferation; Cytarabine; Disease Models, Animal; Disease Progression; Humans; Insulin-Like Growth Factor I; Interleukin-6; Mice; Mice, Transgenic; Microglia; Motor Neuron Disease; Superoxide Dismutase; Transforming Growth Factor beta | 2012 |
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Neoplasm Transplantation; Receptors, CXCR4; Transforming Growth Factor beta; Tumor Microenvironment | 2013 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |